Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $60.08

Janux Therapeutics, Inc. (NASDAQ:JANX) has received an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $60.0833.

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald decreased their target price on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 2nd. HC Wainwright cut their price target on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Piper Sandler lowered their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, January 16th. Wolfe Research initiated coverage on Janux Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. Finally, Clear Str lowered Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th.

Insider Buying and Selling

In related news, insider Charles M. Winter sold 2,401 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $32,965.73. Following the completion of the sale, the insider owned 77,721 shares of the company’s stock, valued at approximately $1,067,109.33. This represents a 3.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas Diraimondo sold 2,505 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $34,393.65. Following the completion of the transaction, the insider owned 124,425 shares in the company, valued at $1,708,355.25. The trade was a 1.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 25,699 shares of company stock worth $471,235. Corporate insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its holdings in shares of Janux Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after acquiring an additional 404 shares in the last quarter. ProShare Advisors LLC increased its holdings in Janux Therapeutics by 8.1% in the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after purchasing an additional 771 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Janux Therapeutics by 25.6% in the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares during the period. Virtus Investment Advisers LLC lifted its stake in shares of Janux Therapeutics by 37.9% during the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares in the last quarter. Finally, DNB Asset Management AS lifted its stake in shares of Janux Therapeutics by 19.2% during the second quarter. DNB Asset Management AS now owns 9,253 shares of the company’s stock worth $214,000 after purchasing an additional 1,488 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 1.4%

Shares of NASDAQ:JANX opened at $13.80 on Friday. The company has a market cap of $830.07 million, a P/E ratio of -8.21 and a beta of 2.88. The business has a fifty day simple moving average of $16.03 and a 200-day simple moving average of $22.12. Janux Therapeutics has a 52 week low of $12.80 and a 52 week high of $45.79.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. Sell-side analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.